Survival time

Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer

L. Liu, Li, C. H., Jin, T. F., and Xu, D. Y., “Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer”, vol. 13, pp. 8722-8728, 2014.

We conducted a cohort study to investigate the role of 2 single-nucleotide polymorphisms of the excision repair cross-complimentary group 1 (ERCC1) gene polymorphism in response to chemotherapy and clinical outcomes of gastric cancer. A total of 231 patients with newly diagnosed and histopathologically confirmed primary gastric cancer participated in the study. ERCC1 rs11615 and rs3212986 were genotyped. Individuals with the ERCC1 rs11615 TT genotype and the T allele showed a significant poorer response to chemotherapy compared to the wild-type genotype.

Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer

H. Gao, Ge, R. C., Liu, H. Y., Wang, Y., and Yan, S., “Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer”, vol. 13, pp. 8997-9004, 2014.

We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair cross-complementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were followed up until December 2012. ERCC1 rs11615, rs3212986, and rs2298881 were selected and genotyped.